Business context and reporting period
Filing identity: The supplied filing is Immudyne, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed May 23, 2017. It does not appear to be a LifeMD, Inc. filing, despite the request metadata.
Immudyne manufactures and sells yeast beta-glucan immune-support ingredients and finished cosmetic products. It consolidated its Puerto Rico joint venture, Immudyne PR, after increasing its ownership to 78.17% in April 2016. The filing describes two segments: nutraceutical and cosmetic additives, and finished cosmetic products.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Net sales | $5.24 million | $1.22 million |
| Gross profit / margin | $3.29 million / 63% | $0.97 million / 80% |
| Operating loss | $1.17 million | $0.26 million |
| Net loss | $1.22 million | $0.16 million |
| Net loss attributable to Immudyne | $1.11 million | $0.06 million |
| Cash from operations | $(0.41) million | $(0.30) million |
| Cash at year-end | $0.18 million | $0.23 million |
Finished cosmetic products generated $4.24 million of 2016 revenue, versus $0.14 million in 2015; additives revenue was approximately $1.0 million, versus $1.08 million. The filing attributes the revenue increase primarily to sales through Immudyne PR. Finished cosmetics recorded a segment loss of $0.39 million, while additives recorded segment income of $0.16 million; corporate expenses were $0.95 million.
Gross margin declined as sales shifted toward lower-margin finished products. Operating expenses rose 262% to $4.47 million, including $1.71 million of marketing expense, $1.25 million of compensation-related expense, $1.03 million of general and administrative expense, and $0.48 million of professional fees. The filing cites advertising and shares issued under joint-venture service agreements as key drivers of the larger loss.
At December 31, 2016, current assets were $0.79 million and current liabilities $1.15 million; working capital was negative $361,725 and the current ratio was 0.69. Year-end liabilities included $100,000 of convertible notes, $106,365 of notes payable net of discount, and $192,254 of derivative liabilities. The company reported accumulated losses of approximately $9.7 million. The filing also reports $1.93 million of customer discounts, returns, and rebates in 2016, not significant in 2015.
Material changes, outlook, and key risks
- Growth and mix: Sales increased 330%, primarily due to the newly consolidated finished-products business. The company said it expected advertising costs to decline as a percentage of sales as Immudyne PR matured, but provided no formal earnings or revenue guidance.
- Liquidity and going concern: The auditor’s report included an explanatory paragraph stating that accumulated losses and negative operating cash flows raised substantial doubt about the company’s ability to continue as a going concern. Management said operations, together with financing completed in 2016 and early 2017, were expected to fund operations through 2017, while warning that additional capital might be needed and was not assured.
- Financing after year-end: The company described 11% subordinated notes issued in 2016 and early 2017, with repayments and conversions reported by the filing date. A March 2017 equity offering had received subscriptions for 2,673,656 shares and generated $614,940, according to the filing. Further equity issuance could dilute existing shareholders.
- Customer and execution risk: The largest customer represented 15% of 2016 sales, down from 73% in 2015; the second-largest represented 2%, down from 12%. The company remains exposed to customer loss, consumer demand, competition, and its ability to successfully market and distribute its products.
- Regulatory and product risk: Products are subject to FDA and FTC requirements, including restrictions on disease-related claims. The company states that research cited for product benefits was not overseen or approved by the FDA. It reported no product liability insurance and identified potential recall, claims, and regulatory risks.
- Controls and governance: Management concluded disclosure controls and internal controls over financial reporting were ineffective and identified material weaknesses, including inadequate segregation of duties, insufficient written procedures, and limited board oversight. The company had no functioning audit committee. Management said remediation depended in part on available funding.
- Unusual equity and related-party matters: Stock-based compensation was $588,000 in 2016. Two joint-venture service providers received 2.3 million shares valued at $690,000; the company reported recognizing $383,333 of expense and retained rescission rights over specified shares after a distribution milestone was missed. The filing also describes financing, office-space, and service arrangements involving officers, directors, shareholders, or their affiliates.
- Other developments: The company said it launched in-licensed ShapiroMD hair-loss shampoo and conditioner in the second quarter of 2017, after the reporting year.
Important facts an investor should verify
- Confirm that this Immudyne, Inc. filing is the intended issuer; it does not match the LifeMD, Inc. metadata.
- Review the audited financial statements and subsequent-event disclosures to reconcile year-end debt balances with repayments and conversions reported by the filing date.
- Assess cash needs and funding availability, given negative working capital, continuing operating cash outflows, and the auditor’s going-concern warning.
- Verify the economics and performance of Immudyne PR, including gross margins, advertising costs, customer returns and rebates, and the status of share rescission rights and distribution milestones.
- Evaluate the effect of outstanding and potentially issuable shares, warrants, options, and derivative liabilities on dilution and liquidity.
- Review progress addressing material weaknesses, customer concentration, product-claim compliance, and the lack of product liability insurance.